肿瘤药学2024，Vol.14Issue(4)：411-419,9.DOI:10.3969/j.issn.2095-1264.2024.04.05
抗体药物偶联物治疗非小细胞肺癌的研究进展和展望
Research progress and prospect of antibody-drug conjugates in the treatment of non-small cell lung cancer
摘要
Abstract
Antibody-drug conjugates(ADCs)represent an emerging anticancer therapeutic strategy that combines the high specificity of monoclonal antibodies with the lethality of highly cytotoxic drugs to fully leverage the advantages of tar-geted therapies.Compared with traditional chemotherapy drugs,ADCs can not only accurately identify tumor targets,but al-so achieve rapid delivery of drugs into tumor cells,providing higher therapeutic efficacy while reducing systemic toxic side effects.ADCs have shown excellent therapeutic effect in a variety of cancer types,and its research and application in the treatment of non-small cell lung cancer has also attracted much attention.This paper reviews the research status and pros-pects of ADCs in the treatment of non-small cell lung cancer.关键词
抗体药物偶联物/非小细胞肺癌/人表皮生长因子受体/滋养层细胞表面抗原2Key words
Antibody-drug conjugates/Non-small cell lung cancer/Human epidermal growth factor receptor/Tropho-blast cell surface antigen 2分类
医药卫生引用本文复制引用
李雨凝,苏佳琳,罗永忠,张乐蒙..抗体药物偶联物治疗非小细胞肺癌的研究进展和展望[J].肿瘤药学,2024,14(4):411-419,9.基金项目
湖南省科技厅自然科学基金(2023JJ60039). （2023JJ60039）
